PharmaCyte Biotech’s Cancer and Diabetes Treatments Airing Nationwide on Discovery Channel
June 29 2015 - 8:30AM
PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage
biotechnology company focused on developing targeted treatments for
cancer and diabetes using its signature live-cell encapsulation
technology, Cell-in-a-Box®, announced today that its technology and
treatments will be featured on the Discovery Channel and ION
Network tomorrow morning, June 30, 2015, from 7:00-7:30 a.m. EDT
and PDT, except on DISH Network which airs using the EDT time zone.
PharmaCyte Biotech’s story will air on Discovery Channel and ION
Network’s news magazine series “NewsWatch,” a source for breaking
consumer, technology, travel, health and entertainment news since
1990.
NewsWatch, based in the Washington, DC area,
airs nationwide in the U.S. and can be seen in virtually every
market throughout the country. Each edition of NewsWatch reaches
more than 96 million U.S. households. Over 700 million people have
viewed the NewsWatch series, making it one of the most successful
independently produced news magazines on television. NewsWatch will
present PharmaCyte Biotech’s story in “HealthWatch,” a segment that
provides viewers with the latest medical breakthroughs and newest
medical advances that can improve their health.
PharmaCyte Biotech’s Chief Executive Officer,
Kenneth L. Waggoner, commented, “We have a great story, and when we
were contacted by NewsWatch to present our technology and the
targeted treatments we’re developing for cancer and diabetes to
their nationwide audience, we jumped at the opportunity. Our
mission is about helping people. We can think of no better way to
connect with people than to have our compelling story air on the
Discovery Channel and ION Network and potentially be seen by the 96
million households they reach in the U.S.”
Since the series began in 1990, NewsWatch has
featured more than 10,000 individual stories on a wide range of
subjects, including medical breakthroughs, finance, travel, new
product introductions, public policy issues, entertainment,
celebrities and numerous other topics.
About PharmaCyte BiotechPharmaCyte Biotech is a
clinical stage biotechnology company focused on developing and
preparing to commercialize treatments for cancer and diabetes based
upon a proprietary cellulose-based live cell encapsulation
technology known as Cell-in-a-Box®. This unique and patented
technology will be used as a platform upon which treatments for
several types of cancer, including advanced, inoperable pancreatic
cancer, and diabetes are being built. PharmaCyte Biotech's
treatment for pancreatic cancer involves low doses of the
well-known chemotherapy prodrug ifosfamide, together with
encapsulated live cells, which convert ifosfamide into its active
or "cancer-killing" form. These capsules are placed as close to the
tumor as possible to enable the delivery of the highest levels of
the cancer-killing drug at the source of the cancer. This "targeted
chemotherapy" has proven remarkably effective in past clinical
trials. PharmaCyte Biotech is also working towards improving the
quality of life for patients with advanced pancreatic cancer and on
treatments for other types of solid cancerous tumors.
In addition, PharmaCyte Biotech is developing
treatments for cancer based upon chemical constituents of the
Cannabis plant, known as cannabinoids. In doing so, PharmaCyte
Biotech is examining ways to exploit the benefits of Cell-in-a-Box®
technology in optimizing the anticancer effectiveness of
cannabinoids, while minimizing or outright eliminating the
debilitating side effects usually associated with cancer
treatments. This provides PharmaCyte Biotech the rare opportunity
to develop “green” approaches to fighting deadly diseases, such as
cancer of the pancreas, brain and breast, which affect hundreds of
thousands of individuals worldwide every year.
Safe HarborThis press release may contain
forward-looking statements regarding PharmaCyte Biotech and its
future events and results that involve inherent risks and
uncertainties. The words "anticipate," "believe," "estimate,"
"expect," "intend," "plan" and similar expressions, as they relate
to PharmaCyte Biotech or its management, are intended to identify
forward-looking statements. Important factors, many of which are
beyond the control of PharmaCyte Biotech, could cause actual
results to differ materially from those set forth in the
forward-looking statements. They include PharmaCyte's ability to
continue as a going concern, delays or unsuccessful results in
preclinical and clinical trials, flaws or defects regarding its
product candidates, changes in relevant legislation or regulatory
requirements, uncertainty of protection of PharmaCyte Biotech’s
intellectual property and PharmaCyte Biotech’s continued ability to
raise capital. PharmaCyte Biotech does not assume any obligation to
update any of these forward-looking statements.
More information about PharmaCyte Biotech can be
found at www.PharmaCyte.com. It can also be obtained by contacting
Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: Info@PharmaCyte.com